Top Premarket Gainers
7:55AM ET 1/04/2022 MT NewswiresAllena Pharmaceuticals (ALNA) shares surged 32% on positive trial data for a treatment candidate for hyperuricemia and gout. NeuroBO Pharmaceuticals (NRBO)...
Allena Pharmaceuticals (ALNA) shares surged 32% on positive trial data for a treatment candidate for hyperuricemia and gout. NeuroBO Pharmaceuticals (NRBO)...
NeuroBo Pharmaceuticals (NRBO) said Wednesday that an independent Data Monitoring Committee recommended the continuation of the company's phase 2/3...
NeuroBo Pharmaceuticals (NRBO) said Tuesday it has sold about 4.3 million shares at $3.25 each, raising around $12.7 million for working capital, capital...
Omeros (OMER) said the US Food and Drug Administration has identified certain deficiencies in a review of its biologics license application for narsoplimab...
Address | 200 Berkeley Street Boston, Massachusetts 02116 |
Phone | +1.857.702.9600 |
Number of Employees | 9 |
Recent SEC Filing | 06/13/2022![]() |
President, Chief Executive & Medical Officer | Ben Gil Price |
Senior Vice President-Operations | Matthew Bardin |
CFO, Secretary, Treasurer & Director | Richard Kang |
Senior Vice President | Andrew Bartynski |
Price Open | $0.47 |
Previous Close | $0.48 |
52 Week Range | $0.37 - 5.63 |
Market Capitalization | $12.5 M |
Shares Outstanding | 26.7 M |
Sector | Health Technology |
Industry | Biotechnology | Next Earnings Announcement | 08/15/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$0.61 |
Beta vs. S&P 500 | N/A |
Revenue | $0.00 |
Net Profit Margin | N/A |
Return on Equity | -140.86% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |